Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis

被引：82

作者：

Sarin, J. ^{[1
]}

DeRossi, S. S. ^{[1
]}

Akintoye, S. O. ^{[1
]}

机构：

[1] Univ Penn, Sch Dent Med, Dept Oral Med, Philadelphia, PA 19104 USA

来源：

ORAL DISEASES | 2008年 / 14卷 / 03期

关键词：

bisphosphonates; jaw; osteonecrosis; biology; bone marrow;

D O I：

10.1111/j.1601-0825.2007.01381.x

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

Osteonecrosis of the jaws is a major complication associated with long-term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate-induced jaw osteonecrosis (BJON) is highly associated with long-term administration of pamidronate (Aredia (R)) and zoledronic acid (Zometa (R)), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site-specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate-induced jaw osteonecrosis.

引用

页码：277 / 285

页数：9

共 49 条

[1] Skeletal site-specific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals [J].

Akintoye, Sunday O. ;

Lam, Thanh ;

Shi, Songtao ;

Brahim, Jaime ;

Collins, Michael T. ;

Robey, Pamela G. .

BONE, 2006, 38 (06) :758-768

[2]

*AM DENT ASS COUNC, 2006, J AM DENT ASSOC, V137, P1144

[3] Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? [J].

Ardine, M. ;

Generali, D. ;

Donadio, M. ;

Bonardi, S. ;

Scoletta, M. ;

Vandone, A. M. ;

Mozzati, M. ;

Bertetto, O. ;

Bottini, A. ;

Dogliotti, L. ;

Berruti, A. .

ANNALS OF ONCOLOGY, 2006, 17 (08) :1336-U4

[4] Factor V Leiden and prothrombin gene mutation [J].

Björkman, A ;

Svensson, PJ ;

Hillarp, A ;

Burtscher, IM ;

Rünow, A ;

Benoni, G .

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2004, (425) :168-172

[5]

BLACK D, 2006, PRIMER METABOLIC BON, P277

[6] Primary prevention of gluccocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone [J].

Boutsen, Y ;

Jamart, J ;

Esselinckx, W ;

Devogelaer, JP .

JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (01) :104-112

[7] Systemic lupus erythematosus in a multiethnic US cohort (LUMINA):: XXIV.: Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients:: results of a nested matched case-control study [J].

Calvo-Alen, J. ;

McGwin, G. ;

Toloza, S. ;

Fernandez, M. ;

Roseman, J. M. ;

Bastian, H. M. ;

Cepeda, E. J. ;

Gonzalez, E. B. ;

Baethge, B. A. ;

Fessler, B. J. ;

Vila, L. M. ;

Reveille, J. D. ;

Alarcon, G. S. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (06) :785-790

[8] Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption [J].

Ezra, A ;

Golomb, G .

ADVANCED DRUG DELIVERY REVIEWS, 2000, 42 (03) :175-195

[9] Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients [J].

Ferretti, G ;

Fabi, A ;

Carlini, P ;

Papaldo, P ;

Fei, PC ;

Di Cosimo, S ;

Salesi, N ;

Giannarelli, D ;

Alimonti, A ;

Di Cocco, B ;

D'Agosto, G ;

Bordignon, V ;

Trento, E ;

Cognetti, F .

ONCOLOGY, 2005, 69 (01) :35-43

[10] Bisphosphonates: Mechanisms of action [J].

Fleisch, H .

ENDOCRINE REVIEWS, 1998, 19 (01) :80-100

← 1 2 3 4 5 →